Type6 Therapeutics

Type6

Type6 develops kinase inhibitors that stabilise proteins in inactive states to treat cancers for the pharmaceutical and drug development industries.

PROSION

This deep-tech company develops small molecule inhibitors to target undruggable proteins for patients with cancer and other serious diseases.

Phost'in Therapeutics

This deep-tech company develops small molecule glycocalyx modifiers to treat patients with aggressive solid tumours by restoring immune responses against cancer cells.

Circle Pharma

This deep-tech company develops macrocycle-based therapies to treat cancer and other serious illnesses for patients requiring targeted medical treatments.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

CasInvent

This company develops selective casein kinase 1 inhibitors to treat resistant cancers, including leukaemias and solid tumours, for patients with limited treatment options.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.